COVCOG: Immediate and long-term cognitive improvement after cognitive versus emotion management psychoeducation programs - a randomized trial in covid patients with neuropsychological difficulties.
Cognitive behavior counseling
Cognitive impairment
Cognitive rehabilitation
Counseling
Long COVID
Post-acute COVID
Psychoeducation
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
18 Aug 2023
18 Aug 2023
Historique:
received:
03
07
2023
accepted:
28
07
2023
medline:
21
8
2023
pubmed:
19
8
2023
entrez:
18
8
2023
Statut:
epublish
Résumé
Cognitive difficulties are a frequent complaint in long COVID and persist for more than a year post- infection. There is a lack of evidence-based data on effective intervention strategies. Non-pharmacological intervention programs that are used with other neurological populations have not yet been the subject of controlled trials. COVCOG is a multicentric, randomized trial comparing cognitive intervention and a cognitive-behavioural counselling. Patients with long covid are selected and recruited at least three months post-infection. Patients are randomised in a 1:1 ratio into the cognitive (neuropsychological psychoeducation) and affective (emotion management with cognitive-behavioural counselling) intervention arms. The inclusion of 130 patients is planned. The cognitive intervention includes psycho-educational modules on fatigue and sleep, attention and working memory, executive functions and long-term memory. The affective intervention includes modules on emotion recognition and communication, uncertainty management and behavioral activation. The main objective is to reduce cognitive complaints 2 months after the intervention. A Follow-up is also planned at 8 months. Given the long-term effects of Covid on cognition and the negative effects of cognitive impairment on quality of life and social participation, it is important to determine whether low-dose, non-pharmacological interventions can be effective. The trial will determine which of the usual types of intervention is the most effective. Clinicaltrials.gov Number: NCT05167266 (21/12/ 2021).
Sections du résumé
BACKGROUND
BACKGROUND
Cognitive difficulties are a frequent complaint in long COVID and persist for more than a year post- infection. There is a lack of evidence-based data on effective intervention strategies. Non-pharmacological intervention programs that are used with other neurological populations have not yet been the subject of controlled trials. COVCOG is a multicentric, randomized trial comparing cognitive intervention and a cognitive-behavioural counselling.
METHODS/DESIGN
METHODS
Patients with long covid are selected and recruited at least three months post-infection. Patients are randomised in a 1:1 ratio into the cognitive (neuropsychological psychoeducation) and affective (emotion management with cognitive-behavioural counselling) intervention arms. The inclusion of 130 patients is planned. The cognitive intervention includes psycho-educational modules on fatigue and sleep, attention and working memory, executive functions and long-term memory. The affective intervention includes modules on emotion recognition and communication, uncertainty management and behavioral activation. The main objective is to reduce cognitive complaints 2 months after the intervention. A Follow-up is also planned at 8 months.
DISCUSSION
CONCLUSIONS
Given the long-term effects of Covid on cognition and the negative effects of cognitive impairment on quality of life and social participation, it is important to determine whether low-dose, non-pharmacological interventions can be effective. The trial will determine which of the usual types of intervention is the most effective.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov Number: NCT05167266 (21/12/ 2021).
Identifiants
pubmed: 37596541
doi: 10.1186/s12883-023-03346-9
pii: 10.1186/s12883-023-03346-9
pmc: PMC10436391
doi:
Banques de données
ClinicalTrials.gov
['NCT05167266']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
307Investigateurs
Michel Moutschen
(M)
Anne-Françoise Rousseau
(AF)
Gilles Dupuis
(G)
Maud Billet
(M)
Maëlle Charonitis
(M)
Valentine Demoulin
(V)
Marie Dethier
(M)
Camille Guillemin
(C)
Fanny Kreusch
(F)
Fréderique Leens
(F)
Christina Léonard
(C)
Alexia Lesoinne
(A)
Florence Requier
(F)
Mathilde Reyt
(M)
Marianne Rotsaert
(M)
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1075-83
pubmed: 27496149
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
J Alzheimers Dis. 2021;81(1):75-81
pubmed: 33720900
Psychother Res. 2012;22(6):638-47
pubmed: 22755547
J Educ Eval Health Prof. 2021;18:17
pubmed: 34325496
J Gerontol B Psychol Sci Soc Sci. 2002 Jan;57(1):P19-27
pubmed: 11773220
Can J Cardiol. 1994 Jan-Feb;10(1):106-12
pubmed: 8111664
Arch Phys Med Rehabil. 2009 Oct;90(10):1672-9
pubmed: 19801055
Lancet. 2021 Aug 28;398(10302):747-758
pubmed: 34454673
J Head Trauma Rehabil. 2023 Jan-Feb 01;38(1):38-51
pubmed: 36594858
J Intern Med. 2022 Feb;291(2):247-251
pubmed: 34569681
Health Psychol. 2012 Nov;31(6):767-76
pubmed: 22746261
Neuropsychol Rehabil. 2023 Aug;33(7):1207-1224
pubmed: 35583357
Sleep. 1991 Aug;14(4):331-8
pubmed: 1947597
AJNR Am J Neuroradiol. 2021 Jul;42(7):1190-1195
pubmed: 33888458
J Clin Neurosci. 2020 Aug;78:449-450
pubmed: 32505431
NeuroRehabilitation. 2010;26(3):239-55
pubmed: 20448314
JAMA Psychiatry. 2021 Jun 1;78(6):682-683
pubmed: 33769431
Arch Clin Neuropsychol. 1996;11(2):139-45
pubmed: 14588914
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
J Neurol Sci. 2023 Jan 15;444:120511
pubmed: 36473347
J Head Trauma Rehabil. 2013 Jul-Aug;28(4):313-22
pubmed: 23640544
Front Psychiatry. 2021 Sep 03;12:725861
pubmed: 34539470
Brain Sci. 2021 Feb 13;11(2):
pubmed: 33668456
Brain. 2021 May 7;144(4):1263-1276
pubmed: 33822001
Brain Behav Immun. 2022 Mar;101:93-135
pubmed: 34973396
J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9
pubmed: 9845158
Neuropsychology. 2009 Jan;23(1):20-39
pubmed: 19210030
Behav Neurol. 2019 May 02;2019:6937832
pubmed: 31191738
J Neurotrauma. 2017 Oct 1;34(19):2713-2720
pubmed: 28335664
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
J Head Trauma Rehabil. 2023 Jan-Feb 01;38(1):83-102
pubmed: 36594861
Eur Arch Psychiatry Clin Neurosci. 2022 Aug;272(5):773-782
pubmed: 34698871
Brain Inj. 2005 Oct;19(11):891-4
pubmed: 16296571
J Head Trauma Rehabil. 2016 May-Jun;31(3):E10-20
pubmed: 26394296
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
Front Hum Neurosci. 2011 Feb 17;5:9
pubmed: 21369362
Lancet Infect Dis. 2020 Nov;20(11):e276-e288
pubmed: 32818434
PLoS One. 2021 Apr 28;16(4):e0250708
pubmed: 33909679
Eur Neuropsychopharmacol. 2021 May;46:39-48
pubmed: 33823427
J Head Trauma Rehabil. 2021 Jul-Aug 01;36(4):E249-E261
pubmed: 33656475
Brain Inj. 2012;26(13-14):1646-57
pubmed: 22876936
J Head Trauma Rehabil. 2023 Jan-Feb 01;38(1):52-64
pubmed: 36594859
J Psychiatr Res. 2020 Oct;129:98-102
pubmed: 32912598
Clin Microbiol Infect. 2021 Sep;27(9):1196-1198
pubmed: 34015528
J Neurol. 2021 Sep;268(9):3059-3071
pubmed: 33486564
Can J Neurol Sci. 1994 Feb;21(1):9-14
pubmed: 8180914
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Brain Sci. 2017 Aug 17;7(8):
pubmed: 28817065